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Abstract 
Background: Due to the development of drugs and With regard to this matter that customers of health 
services are unable to assess the clinical and financial aspects of medical technologies, evaluation the 
clinical efficacy of drugs is avery important. The Study aim was to evaluate the clinical efficacy of 
zoledronic acid in the prevention and treatment of postmenopausal osteoporosis.  
Methods: This study was a systematic review. Cochrane, PubMed and Google scholar databases were 
searched using keywords: “Bone mineral density, Male Osteoporosis, Zoledronic acid postmenopausal 
women osteoporosis”. Inclusion criteria were all menopausal women at risk of osteoporosis or 
suffering from it that have been used zoledronic acid at least once for the prevention or treatment of 
osteoporosis. Desired outcomes include reduced bone fractures, bone resorption and bone turnover 
markers, increase bone density, significant improvement in health-related quality of life in patients 
who have had a fracture. The designs of included studies were randomized clinical trials and their 
languages were English. 
Findings: The use of zoledronic acid significantly increased BMD at the total hip, lumbar spine, 
femoral neck, hip trochanter, the distal radius, reduced the incidence of hip fractures, morphometric 
vertebral fractures, vertebral fractures, any clinical fracture, clinical vertebral fractures, risk of non-
vertebral fracture and decreased bone turnover markers in the intervention group compared with the 
control group. 
Conclusion: According to safety and clinical effectiveness of zoledronic acid, using this medication in 
the prevention and treatment of osteoporosis in postmenopausal women is recommended. 
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